BioCentury
ARTICLE | Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

April 5, 2018 10:09 PM UTC

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi (SB5), in the EU on Oct. 16, 2018. and in the U.S. on June 30, 2023.

Samsung Bioepis will pay AbbVie undisclosed royalties on Imraldi sales and gains a non-exclusive license to Humira IP in certain countries. Specific terms are not disclosed...